Vasileia Kalaitzaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vasileia Kalaitzaki has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Thorsten Buch
Institute of Laboratory Animal Science, University of Zurich, Schlieren, Switzerland
3 shared publications - Andreas Lutterotti
Cellerys AG, Wagistrasse 21, Schlieren, Switzerland
2 shared publications - Antonis Katsoulas
Institute of Laboratory Animal Science, University of Zurich, Schlieren, Switzerland
2 shared publications - Filipa Marques Ferreira
Institute of Laboratory Animal Science, University of Zurich, Schlieren, Switzerland
2 shared publications - Pietro Oldrati
Cellerys AG, Wagistrasse 21, Schlieren, Switzerland
2 shared publications - Roland Martin
Institute of Experimental Immunology, University of Zurich, 8057 Zurich, Switzerland; Cellerys AG, Wagistrasse 21, 8952 Schlieren, Switzerland; Neuroimmunology and MS Research, Neurology Clinic, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland; Therapeutic Immune Design Unit, Department of Clinical Neuroscience, Karolinska Institute, Center for Molecular Medicine, 17177 Stockholm, Sweden
2 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (41)
Kupffer cells are key mediators of antigen-specific immune tolerance by peptide-coupled red blood cells
Induction of antigen-specific immune tolerance is the most precise method for reverting an autoreactive immune response in diseases such as multiple sclerosis (MS). Coupling red blood cells (RBCs) with a cocktail of MS immunodominant peptides is a promising approach to induce antigen-specific immune tolerance in patients. Here, we show that RBCs coupled with disease-inducing antigen efficiently prevent the development of experimental autoimmune encephalomyelitis, when administered prophylactically, and ameliorate disease symptoms when given therapeutically. The tolerogenic activity of peptide-coupled RBCs (pcRBC) was antigen specific and dependent on both cell and peptide dose. Kupffer cells (KC) were the primary phagocytes of pcRBC, and their uptake of pcRBC did not require complement component 3, SIRPα, and Stabilin 1 and 2. KC were indispensable for the induction of tolerance, which was accompanied by programmed death-ligand 1 up-regulation and a tolerogenic transcriptional shift. Our findings establish KC as central mediators of pcRBC-induced immune tolerance and provide mechanistic insight for the use of this therapeutic strategy in autoimmune disease.
- 9 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (41)
Open AccessKupffer cells are key mediators of antigen-specific immune tolerance by peptide-coupled red blood cells
Induction of antigen-specific immune tolerance is the most precise method for reverting an autoreactive immune response in diseases such as multiple sclerosis (MS). Coupling red blood cells (RBCs) with a cocktail of MS immunodominant peptides is a promising approach to induce antigen-specific immune tolerance in patients. Here, we show that RBCs coupled with disease-inducing antigen efficiently prevent the development of experimental autoimmune encephalomyelitis, when administered prophylactically, and ameliorate disease symptoms when given therapeutically. The tolerogenic activity of peptide-coupled RBCs (pcRBC) was antigen specific and dependent on both cell and peptide dose. Kupffer cells (KC) were the primary phagocytes of pcRBC, and their uptake of pcRBC did not require complement component 3, SIRPα, and Stabilin 1 and 2. KC were indispensable for the induction of tolerance, which was accompanied by programmed death-ligand 1 up-regulation and a tolerogenic transcriptional shift. Our findings establish KC as central mediators of pcRBC-induced immune tolerance and provide mechanistic insight for the use of this therapeutic strategy in autoimmune disease.
- Open Access
- 31 August 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (36)
Treatment of multiple sclerosis with peptide-coupled red blood cells induces antigen-specific T regulatory cells
Inducing antigen-specific immune tolerance is a long-standing aim in organ-specific autoimmune diseases including multiple sclerosis (MS). We developed a therapy based on autologous red blood cells (RBCs) as tolerizing carriers of autoantigens and tested these in an open-label, dose-escalation, phase Ib clinical trial with clinical, imaging, and mechanistic readouts. RBCs coupled with seven immunodominant myelin peptides (pcRBCs) were safe and well tolerated. Several clinical and imaging readouts remained stable, which was supported by a reduction of neurofilament light chain indicating reduced tissue inflammation in the brain. Single-cell RNA sequencing identified expansion of antigen-specific CD4+ memory T cells with regulatory phenotypes and loss of proinflammatory cells three months after a single administration of pcRBCs. This was corroborated by a reduction of autoreactive CD4+ T cell responses and an early increase of IL-10, Tr1 regulatory T cells and tolerogenic monocytes and plasmacytoid dendritic cells. Biodistribution studies in mice and humans demonstrate that pcRBCs are rapidly processed by Kupffer cells in the liver and by marginal zone macrophages in the spleen. In summary, pcRBCs are a promising autologous cell therapy for achieving antigen-specific immune tolerance in MS.
- 31 August 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (36)
Open AccessTreatment of multiple sclerosis with peptide-coupled red blood cells induces antigen-specific T regulatory cells
Inducing antigen-specific immune tolerance is a long-standing aim in organ-specific autoimmune diseases including multiple sclerosis (MS). We developed a therapy based on autologous red blood cells (RBCs) as tolerizing carriers of autoantigens and tested these in an open-label, dose-escalation, phase Ib clinical trial with clinical, imaging, and mechanistic readouts. RBCs coupled with seven immunodominant myelin peptides (pcRBCs) were safe and well tolerated. Several clinical and imaging readouts remained stable, which was supported by a reduction of neurofilament light chain indicating reduced tissue inflammation in the brain. Single-cell RNA sequencing identified expansion of antigen-specific CD4+ memory T cells with regulatory phenotypes and loss of proinflammatory cells three months after a single administration of pcRBCs. This was corroborated by a reduction of autoreactive CD4+ T cell responses and an early increase of IL-10, Tr1 regulatory T cells and tolerogenic monocytes and plasmacytoid dendritic cells. Biodistribution studies in mice and humans demonstrate that pcRBCs are rapidly processed by Kupffer cells in the liver and by marginal zone macrophages in the spleen. In summary, pcRBCs are a promising autologous cell therapy for achieving antigen-specific immune tolerance in MS.
- Open Access
IGF1R expression by adult oligodendrocytes is not required in the steady‐state but supports neuroinflammation
In the central nervous system (CNS), insulin-like growth factor 1 (IGF-1) regulates myelination by oligodendrocyte (ODC) precursor cells and shows anti-apoptotic properties in neuronal cells in different in vitro and in vivo systems. Previous work also suggests that IGF-1 protects ODCs from cell death and enhances remyelination in models of toxin-induced and autoimmune demyelination. However, since evidence remains controversial, the therapeutic potential of IGF-1 in demyelinating CNS conditions is unclear. To finally shed light on the function of IGF1-signaling for ODCs, we deleted insulin-like growth factor 1 receptor (IGF1R) specifically in mature ODCs of the mouse. We found that ODC survival and myelin status were unaffected by the absence of IGF1R until 15 months of age, indicating that IGF-1 signaling does not play a major role in post-mitotic ODCs during homeostasis. Notably, the absence of IGF1R did neither affect ODC survival nor myelin status upon cuprizone intoxication or induction of experimental autoimmune encephalomyelitis (EAE), models for toxic and autoimmune demyelination, respectively. Surprisingly, however, the absence of IGF1R from ODCs protected against clinical neuroinflammation in the EAE model. Together, our data indicate that IGF-1 signaling is not required for the function and survival of mature ODCs in steady-state and disease.
Open AccessIGF1R expression by adult oligodendrocytes is not required in the steady‐state but supports neuroinflammation
In the central nervous system (CNS), insulin-like growth factor 1 (IGF-1) regulates myelination by oligodendrocyte (ODC) precursor cells and shows anti-apoptotic properties in neuronal cells in different in vitro and in vivo systems. Previous work also suggests that IGF-1 protects ODCs from cell death and enhances remyelination in models of toxin-induced and autoimmune demyelination. However, since evidence remains controversial, the therapeutic potential of IGF-1 in demyelinating CNS conditions is unclear. To finally shed light on the function of IGF1-signaling for ODCs, we deleted insulin-like growth factor 1 receptor (IGF1R) specifically in mature ODCs of the mouse. We found that ODC survival and myelin status were unaffected by the absence of IGF1R until 15 months of age, indicating that IGF-1 signaling does not play a major role in post-mitotic ODCs during homeostasis. Notably, the absence of IGF1R did neither affect ODC survival nor myelin status upon cuprizone intoxication or induction of experimental autoimmune encephalomyelitis (EAE), models for toxic and autoimmune demyelination, respectively. Surprisingly, however, the absence of IGF1R from ODCs protected against clinical neuroinflammation in the EAE model. Together, our data indicate that IGF-1 signaling is not required for the function and survival of mature ODCs in steady-state and disease.